Whereas the FDA-approved drug niclosamide that blocks TMEM16F-dependent syncytia formation is under examination in clinical trials24,25 (clinicaltrials.gov) for treatment of severe COVID-19, niclosamide also inhibits TMEM16A and mitigates the symptoms of airway diseases in mice26,27. Here, ANO1 is linked to COVID-19.